Intellectus Partners LLC Sells 2,286 Shares of Amgen Inc. $AMGN

Intellectus Partners LLC decreased its holdings in Amgen Inc. (NASDAQ:AMGN) by 70.9% during the 4th quarter, HoldingsChannel.com reports. The firm owned 938 shares of the medical research company’s stock after selling 2,286 shares during the period. Intellectus Partners LLC’s holdings in Amgen were worth $307,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the business. High Note Wealth LLC grew its stake in shares of Amgen by 5.8% in the fourth quarter. High Note Wealth LLC now owns 508 shares of the medical research company’s stock worth $166,000 after purchasing an additional 28 shares during the last quarter. TAGStone Capital Inc. lifted its holdings in Amgen by 0.7% in the fourth quarter. TAGStone Capital Inc. now owns 4,129 shares of the medical research company’s stock valued at $1,351,000 after buying an additional 28 shares during the period. West Family Investments Inc. lifted its holdings in Amgen by 1.1% in the third quarter. West Family Investments Inc. now owns 2,760 shares of the medical research company’s stock valued at $779,000 after buying an additional 30 shares during the period. Viawealth LLC raised its holdings in shares of Amgen by 0.4% during the third quarter. Viawealth LLC now owns 7,168 shares of the medical research company’s stock valued at $2,023,000 after purchasing an additional 30 shares during the period. Finally, LOM Asset Management Ltd raised its holdings in shares of Amgen by 1.2% during the third quarter. LOM Asset Management Ltd now owns 2,554 shares of the medical research company’s stock valued at $721,000 after purchasing an additional 30 shares during the period. Institutional investors own 76.50% of the company’s stock.

Key Headlines Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen received European Commission approval for Imdelltra, a regulatory win that could expand its cancer-treatment revenue opportunity in Europe. EC approval for Amgen’s Imdylltra
• Positive Sentiment: Amgen said it will present new data across rare autoimmune and inflammatory diseases at EULAR 2026, with updates supporting UPLIZNA and TAVNEOS, which may reinforce confidence in its specialty-drug growth. Amgen to Present New Data Across Rare Autoimmune and Inflammatory Diseases at EULAR 2026
• Positive Sentiment: Amgen announced it will present at the Goldman Sachs 47th Annual Global Healthcare Conference, which could keep investor focus on its strategy and pipeline progress. Amgen to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
• Neutral Sentiment: Amgen’s appearance at the Jefferies Global Healthcare Conference is keeping the stock in the spotlight, but the transcript itself does not add a clear new catalyst. Amgen Inc. (AMGN) Presents at Jefferies Global Healthcare Conference 2026 Transcript
• Neutral Sentiment: Amgen is also getting some broader attention from commentary on AI adoption in biotech and analyst notes on healthcare names, but these items appear more informational than stock-moving. The CEO who loves AI autodidacts — and desperately needs his experts Analysts Offer Insights on Healthcare Companies: Amgen (AMGN) and Thermo Fisher (TMO)

Amgen Stock Up 2.2%

Shares of NASDAQ:AMGN opened at $345.60 on Friday. The firm has a fifty day moving average price of $341.44 and a two-hundred day moving average price of $345.44. The company has a debt-to-equity ratio of 5.65, a current ratio of 1.26 and a quick ratio of 1.01. Amgen Inc. has a one year low of $267.83 and a one year high of $391.29. The company has a market cap of $186.52 billion, a price-to-earnings ratio of 24.05, a PEG ratio of 3.39 and a beta of 0.42.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, beating the consensus estimate of $4.77 by $0.38. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The firm had revenue of $8.62 billion during the quarter, compared to the consensus estimate of $8.58 billion. During the same period last year, the firm earned $4.90 EPS. The business’s quarterly revenue was up 5.8% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. Analysts anticipate that Amgen Inc. will post 22.38 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

AMGN has been the topic of several research reports. UBS Group upped their price objective on shares of Amgen from $390.00 to $400.00 and gave the company a “buy” rating in a report on Monday, April 13th. Daiwa Securities Group reduced their price objective on shares of Amgen from $410.00 to $390.00 and set an “outperform” rating for the company in a research report on Wednesday, May 13th. Deutsche Bank Aktiengesellschaft increased their target price on shares of Amgen from $285.00 to $295.00 and gave the company a “hold” rating in a research report on Thursday, February 5th. Piper Sandler reduced their target price on shares of Amgen from $432.00 to $427.00 and set an “overweight” rating for the company in a research report on Thursday, May 14th. Finally, Truist Financial upped their price target on shares of Amgen from $325.00 to $327.00 and gave the company a “hold” rating in a research note on Friday, May 1st. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, fourteen have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, Amgen has an average rating of “Hold” and an average price target of $355.19.

Insider Buying and Selling

In other Amgen news, SVP Nancy A. Grygiel sold 1,237 shares of the firm’s stock in a transaction on Monday, May 4th. The shares were sold at an average price of $323.73, for a total value of $400,454.01. Following the completion of the transaction, the senior vice president directly owned 7,009 shares of the company’s stock, valued at $2,269,023.57. This trade represents a 15.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.85% of the stock is currently owned by insiders.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.